AZR — Azora Therapeutics Share News
0.000.00%
Last trade - 00:00Adial Pharmaceuticals Inc expected to post a loss of 49 cents a share - Earnings Preview
Adial Pharmaceuticals Inc expected to post a loss of 49 cents a share - Earnings Preview
Brief: Adial Pharmaceuticals Granted End Of Phase 2 Meeting From FDA
U.S. STOCKS ON THE MOVE-Maze Therapeutics, UFP Technologies, Itron
U.S. STOCKS ON THE MOVE-AxoGen, Portillo, Cisco Systems
Adial Pharma jumps on regulatory pathway for alcohol-use disorder drug
Brief: Adial Pharma Receives Positive Response From FDA Meeting Regarding Vitro Bridging Strategy For AD04
Brief: Adial Pharmaceuticals Granted New U.S. Patent On Method To Identify Genetic Markers In Alcohol or Opioid-Related Disorders
Brief: Adial Pharmaceuticals Inc - Prospectus Relates To Resale Of Up To 5 Million Shares Offered By Alumni Capital
Brief: Adial Pharmaceuticals Inc - On Dec 13, Enters Purchase Agreement With Alumni Capital
U.S. STOCKS ON THE MOVE-Talen Energy, Biogen, Ovintiv
U.S. STOCKS ON THE MOVE-Oklo, Adial Pharma, Sonos
Adial Pharmaceuticals Inc reports results for the quarter ended September 30 - Earnings Summary
Adial Pharma jumps on data for alcohol abuse drug
Adial Pharmaceuticals Inc expected to post a loss of 44 cents a share - Earnings Preview
Brief: Adial Advances To Second Cohort In Pharmacokinetics Study Of Ad04
Brief: Adial Pharmaceuticals Achieves Important Milestone of First Patient Dosed in Pharmacokinetics Study of AD04 for the Treatment of Alcohol Use Disorder
Adial Pharmaceuticals Inc expected to post a loss of 33 cents a share - Earnings Preview
Brief: Adial Pharmaceuticals Granted Key Patent From The United States Patent And Trademark Office